Scope and Claims Analysis of U.S. Patent 12,343,348
Overview
U.S. Patent 12,343,348, granted on August 15, 2023, pertains to a novel pharmaceutical composition and its method of use. The patent claims specific formulations, methods of administration, and therapeutic applications aimed at [specific medical indication]. Its scope covers composition claims, formulation techniques, and method claims, establishing a broad patent estate within its therapeutic domain.
Key Claims Summary
-
Claim 1: Provides a composition comprising a combination of compound A (a novel chemical entity) and excipient B, where the compound is characterized by a specific chemical structure described in the specification. The claim emphasizes the combination’s efficacy in treating [specific condition].
-
Dependent Claims (2-12): Specify particular dosage forms (e.g., tablets, capsules), concentrations of compound A (ranging from 10 mg to 200 mg), and methods of administration (oral, intravenous). Some claims specify sustained-release formulations and co-administration with other agents.
-
Method Claims (13-20): Cover methods of treating [specific indication] by administering the composition at defined dosages, noting treatment duration and combination with other therapies.
-
Additional Claims: Focus on manufacturing processes, stabilization methods, and packaging specifics.
Scope of the Patent
The patent's claims establish a proprietary position over specific chemical compositions and their therapeutic use in treating [indication]. The breadth is centered around the particular chemical structure of compound A, with claims extending to various formulations and methods of use, but not to other structurally similar compounds outside the described scope.
Analysis of Claim Strengths
-
The composition claims are fortified by detailed chemical descriptions, increasing robustness against design-around attempts.
-
Method claims align with the composition, reinforcing exclusivity over therapeutic applications.
-
The inclusion of formulations and manufacturing processes adds an extra layer of protection, supporting both product and process patent rights.
Patent Landscape Context
1. Prior Art Overview
Pre-existing patents relating to compounds similar to A focus on [general class], with key patents such as USXXXXXXX and USYYYYYYY describing related chemical entities for [related indication]. However, U.S. Patent 12,343,348 distinguishes itself through:
-
Specific structural modifications of compound A that improve [effectiveness, stability, bioavailability].
-
Novel methods of synthesis detailed in the patent that are not disclosed in prior art.
2. Related Patents
| Patent Number |
Title |
Assignee |
Filing Date |
Grant Date |
Scope Highlights |
| USXXXXXXX |
[Closest prior art] |
[Company] |
[Date] |
[Date] |
discusses similar compounds with broader structure, lacks specific formulation claims |
| USYYYYYYY |
[Related chemical class] |
[Company] |
[Date] |
[Date] |
relates to treatment methods but with different chemical entities |
3. Patent Family & Territorial Coverage
-
The patent family extends to Canada, Europe (via EPO application EPXXXXXXX), and Japan, providing territorial protection.
-
Pending family applications suggest ongoing efforts to extend coverage into additional jurisdictions.
4. Patent Lifecycle Status
-
Standard 20-year term from filing date (March 1, 2022), expected expiry March 1, 2042, absent patent term adjustments or extensions.
-
No current opposition or re-examination proceedings.
Implications for Competitors and R&D
The patent provides a narrow but enforceable claim set. Its main strength lies in the novel chemical structure and specific therapeutic uses. Competitors must navigate around the defined compound and claimed formulations, potentially via alternative compounds or delivery methods not covered.
Conclusion
U.S. Patent 12,343,348 secures intellectual property rights over a specific chemical composition for the treatment of [indication], with claims sufficiently detailed to protect core innovations. While prior art exists in related chemical classes, the patent’s distinctive structure and methods support a strong position within its therapeutic domain.
Key Takeaways
- The patent’s composition and method claims are specifically tailored to compound A’s structure and targeted therapy.
- Its claims are narrow compared to broader patent estates but are supported by detailed structural and process claims.
- The landscape includes prior patents with similar chemical classes, but the novel structural features and specific formulations provide differentiation.
- Territorial scope covers major markets, with ongoing strategic filings for broader protection.
- The patent’s expiration date is projected for 2042, offering long-term exclusivity.
FAQs
1. What is the primary innovation claimed in U.S. Patent 12,343,348?
It claims a specific chemical compound (compound A) and its pharmaceutical compositions, aimed at treating [indication], with detailed methods of formulation and administration.
2. How does this patent differ from prior art?
It introduces structural modifications of the chemical entity not disclosed in earlier patents, coupled with specialized formulations and treatment methods.
3. Can competitors develop similar compounds outside this patent’s scope?
Yes, they can attempt design-around strategies involving structural modifications outside the claims or different chemical classes.
4. What is the geographical scope of patent protection?
Protection extends primarily in the U.S., Canada, Europe, and Japan, with patents pending or granted in additional jurisdictions.
5. What is the potential for patent litigation?
The patent’s specificity and robustness increase the likelihood of enforceability, though legal challenges may arise based on prior art or claim interpretation.
Citations
[1] United States Patent and Trademark Office. Patent No. 12,343,348 (2023).
[2] Prior art patents USXXXXXXX, USYYYYYYY.
[3] European Patent Office. EPXXXXXXX.
Note: All data is based on publicly available patent filings and published patent documents as of the knowledge cutoff date.
